Response and survival in oesophageal cancer patients following neoadjuvant chemotherapy assessed by FDG-PETCT imaging and corelation to pathologic response.

e14571 Background: Combined positron emission tomography with computed tomography(PETCT) using [18F] 2-fluoro-2-deoxy-D-glucose (FDG) is an important modality for staging oesophageal cancer and may also predict pathological response to chemotherapy. We therefore conducted this retrospective review to assess the relationship between metabolic response measured by FDG-PETCT imaging following neoadjuvant chemotherapy in oesophageal cancer and survival. Methods: Oesophageal cancer patients presenting to Northern Ireland Cancer Centre between January 2003 to December 2008, who had FDG-PETCT assessment for staging and also following neoadjuvant chemotherapy before surgery were included. Routine FDG-PETCT findings were collated and metabolic response (≥ 35% reduction in the tumour standard uptake values[SUV]), evaluated. Pathologic response was assessed and stratified into five histological tumour regression grades (TRG1-5). TRG 1 and 2 groups were classified as pathological responders. Overall survival and even...